• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

欧洲患者中 Dupuytren 挛缩症行筋膜切除术和筋膜切开术的疗效及安全性:已发表研究的结构化综述

The efficacy and safety of fasciectomy and fasciotomy for Dupuytren's contracture in European patients: a structured review of published studies.

作者信息

Crean S M, Gerber R A, Le Graverand M P Hellio, Boyd D M, Cappelleri J C

机构信息

United BioSource Corporation, Lexington, MA 02420, USA.

出版信息

J Hand Surg Eur Vol. 2011 Jun;36(5):396-407. doi: 10.1177/1753193410397971. Epub 2011 Mar 7.

DOI:10.1177/1753193410397971
PMID:21382860
Abstract

A structured review of published papers was done to assess the efficacy and safety of fasciectomy and fasciotomy in European patients with Dupuytren's contracture. The outcomes varied across 48 studies. For fasciectomy, outcomes and results were as follows: the proportions of patients with a 100% correction in contracture angle ranged from 61 to 97%, the mean improvement in contracture angle ranged from 58 to 79%, and cases judged excellent/good ranged from 63 to 90%. Fasciotomy had similar outcomes, with a mean improvement in contracture angle ranging from 46 to 88%. Immediate failures upon recovery were reported for both procedures. The average recurrence rates were 39% after a fasciectomy and 62% after a fasciotomy at a median time of about 4 years. Overall, about 20% of fasciectomy and fasciotomy patients experienced an adverse event. In summary, postoperative outcomes were successful, but surgical complications were common and recurrence of a contracture was likely within a few years.

摘要

对已发表论文进行了结构化综述,以评估筋膜切除术和筋膜切开术在欧洲杜普伊特伦挛缩症患者中的疗效和安全性。48项研究的结果各不相同。对于筋膜切除术,结果如下:挛缩角矫正100%的患者比例在61%至97%之间,挛缩角的平均改善幅度在58%至79%之间,评定为优秀/良好的病例在63%至90%之间。筋膜切开术有类似结果,挛缩角的平均改善幅度在46%至88%之间。两种手术均报告了恢复时的即刻失败情况。筋膜切除术后平均复发率在约4年的中位时间为39%,筋膜切开术后为62%。总体而言,约20%的筋膜切除术和筋膜切开术患者经历了不良事件。总之,术后结果是成功的,但手术并发症很常见,挛缩可能在几年内复发。

相似文献

1
The efficacy and safety of fasciectomy and fasciotomy for Dupuytren's contracture in European patients: a structured review of published studies.欧洲患者中 Dupuytren 挛缩症行筋膜切除术和筋膜切开术的疗效及安全性:已发表研究的结构化综述
J Hand Surg Eur Vol. 2011 Jun;36(5):396-407. doi: 10.1177/1753193410397971. Epub 2011 Mar 7.
2
Dupuytren's contracture: an analysis of outcomes of percutaneous needle fasciotomy versus open fasciectomy.杜普伊特伦挛缩症:经皮针状筋膜切开术与开放性筋膜切除术的疗效分析
ANZ J Surg. 2015 Sep;85(9):639-43. doi: 10.1111/ans.12513. Epub 2014 Jan 20.
3
Results of surgical treatment of Dupuytren's disease in women: a review of 109 consecutive patients.女性掌腱膜挛缩症的外科治疗结果:109例连续患者的回顾
J Hand Surg Am. 2007 Nov;32(9):1423-8. doi: 10.1016/j.jhsa.2007.06.015.
4
A feasibility study investigating the acceptability and design of a multicentre randomised controlled trial of needle fasciotomy versus limited fasciectomy for the treatment of Dupuytren's contractures of the fingers (HAND-1): study protocol for a randomised controlled trial.一项关于针状筋膜切开术与有限筋膜切除术治疗手指掌腱膜挛缩症的多中心随机对照试验的可接受性和设计的可行性研究(HAND-1):一项随机对照试验的研究方案
Trials. 2017 Aug 25;18(1):392. doi: 10.1186/s13063-017-2127-9.
5
[The treatment of Dupuytren's contracture by partial fasciectomy].
Lijec Vjesn. 1999 Sep-Oct;121(9-10):291-5.
6
Limited fasciectomy with versus without autologous adipose tissue grafting for treatment of Dupuytren's contracture (REMEDY): study protocol for a multicentre randomised controlled trial.局限性掌腱膜切除术联合与不联合自体脂肪组织移植治疗掌腱膜挛缩症(REMEDY):一项多中心随机对照试验的研究方案。
Trials. 2024 Sep 2;25(1):577. doi: 10.1186/s13063-024-08410-4.
7
Severe contractures of the proximal interphalangeal joint in Dupuytren's disease: combined fasciectomy with capsuloligamentous release versus fasciectomy alone.Dupuytren病近端指间关节的严重挛缩:联合筋膜切除术与关节囊韧带松解术对比单纯筋膜切除术
Plast Reconstr Surg. 1996 Mar;97(3):560-6; discussion 567. doi: 10.1097/00006534-199603000-00011.
8
Hueston revisited: use of acellular dermal matrix following fasciectomy for the treatment of Dupuytren's disease.休斯顿再探讨:筋膜切除术后使用脱细胞真皮基质治疗掌腱膜挛缩症。
Ann Plast Surg. 2014 Dec;73 Suppl 2:S178-80. doi: 10.1097/SAP.0000000000000133.
9
Treatment of Dupuytren's contracture. Long-term results after fasciotomy and fascial excision.
J Bone Joint Surg Am. 1976 Apr;58(3):380-7.
10
Safety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren's contracture.溶组织梭状芽孢杆菌胶原酶与筋膜切除术治疗掌腱膜挛缩症的安全性与耐受性
J Hand Surg Eur Vol. 2015 Feb;40(2):141-9. doi: 10.1177/1753193414528843. Epub 2014 Apr 2.

引用本文的文献

1
Angiotensin Receptor Blockers Are Not Associated With Protective Benefits in Dupuytren's Disease.血管紧张素受体阻滞剂与掌腱膜挛缩症的保护益处无关。
Hand (N Y). 2025 Jun 12:15589447251343237. doi: 10.1177/15589447251343237.
2
Early postinterventional clinical implications of Collagenase Clostridium Histolyticum injection versus limited fasciectomy for Dupuytren's disease.注射溶组织梭状芽孢杆菌胶原酶与有限筋膜切除术治疗掌腱膜挛缩症的介入后早期临床影响
J Hand Microsurg. 2025 Apr 25;17(4):100268. doi: 10.1016/j.jham.2025.100268. eCollection 2025 Jul.
3
Collagenase Versus Needle Fasciotomy for Primary Metacarpophalangeal Dupuytren Contracture: Five-Year Results from a Randomized Controlled Trial.
胶原酶与经皮针式筋膜切开术治疗原发性掌指关节杜普伊特伦挛缩症:一项随机对照试验的五年结果
JB JS Open Access. 2024 Nov 20;9(4). doi: 10.2106/JBJS.OA.24.00038. eCollection 2024 Oct-Dec.
4
Collagenase clostridium histolyticum injection versus limited fasciectomy for the treatment of Dupuytren's disease: a systematic review and meta-analysis of comparative studies.胶原酶注射与有限筋膜切开术治疗杜普伊特伦挛缩症的比较:系统评价和荟萃分析。
Arch Orthop Trauma Surg. 2024 Jan;144(1):527-536. doi: 10.1007/s00402-023-05004-8. Epub 2023 Sep 4.
5
Surgical Management of Dupuytren Disease: A Systematic Review and Network Meta-analyses.《掌腱膜挛缩症的外科治疗:系统评价和网络荟萃分析》。
Hand (N Y). 2024 Nov;19(8):1283-1292. doi: 10.1177/15589447231174175. Epub 2023 May 28.
6
Acute Pain Intensity After Collagenase Injection in Patients With Dupuytren Contracture.掌腱膜挛缩症患者注射胶原酶后的急性疼痛强度
J Hand Surg Glob Online. 2019 Nov 27;2(1):16-20. doi: 10.1016/j.jhsg.2019.10.004. eCollection 2020 Jan.
7
Dupuytren's disease: using needles more across the world.掌腱膜挛缩症:全球更多地使用针具。
J Hand Surg Eur Vol. 2022 Jan;47(1):80-88. doi: 10.1177/17531934211043307. Epub 2021 Sep 9.
8
External Screw-Threaded Traction Device Helps Optimize Finger Joint Mobility in Severe Stage III and IV Dupuytren Disease.外螺纹牵引装置有助于优化严重 III 期和 IV 期杜普伊特伦病手指关节的活动度。
Med Sci Monit. 2021 Apr 22;27:e929814. doi: 10.12659/MSM.929814.
9
Cost-effectiveness of Recurrent Dupuytren Contracture Treatment.复发性掌腱膜挛缩治疗的成本效益。
JAMA Netw Open. 2020 Oct 1;3(10):e2019861. doi: 10.1001/jamanetworkopen.2020.19861.
10
A randomised feasibility trial comparing needle fasciotomy with limited fasciectomy treatment for Dupuytren's contractures.一项比较针对掌腱膜挛缩症的针刀筋膜切开术与有限筋膜切除术治疗效果的随机可行性试验。
Pilot Feasibility Stud. 2020 Jan 30;6:7. doi: 10.1186/s40814-019-0546-y. eCollection 2020.